We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Teva Generic Focalin Approval Embroiled in Patent Litigation
Teva Generic Focalin Approval Embroiled in Patent Litigation
February 6, 2007
Despite being the first to win final FDA approval — with 180 days of exclusivity — to manufacture and market generic Focalin, Teva Pharmaceutical still has to prevail in court against Novartis and Celgene.